235 related articles for article (PubMed ID: 22787177)
1. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes.
Bergenstal RM; Rosenstock J; Arakaki RF; Prince MJ; Qu Y; Sinha VP; Howey DC; Jacober SJ
Diabetes Care; 2012 Nov; 35(11):2140-7. PubMed ID: 22787177
[TBL] [Abstract][Full Text] [Related]
2. Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine.
Bergenstal RM; Rosenstock J; Bastyr EJ; Prince MJ; Qu Y; Jacober SJ
Diabetes Care; 2014; 37(3):659-65. PubMed ID: 24198302
[TBL] [Abstract][Full Text] [Related]
3. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study.
Rosenstock J; Bergenstal RM; Blevins TC; Morrow LA; Prince MJ; Qu Y; Sinha VP; Howey DC; Jacober SJ
Diabetes Care; 2013 Mar; 36(3):522-8. PubMed ID: 23193209
[TBL] [Abstract][Full Text] [Related]
4. Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM.
Jacober SJ; Rosenstock J; Bergenstal RM; Prince MJ; Qu Y; Beals JM
Diabetes Obes Metab; 2014 Apr; 16(4):351-6. PubMed ID: 24719911
[TBL] [Abstract][Full Text] [Related]
5. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
6. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.
Rosenstock J; Fonseca VA; Gross JL; Ratner RE; Ahrén B; Chow FC; Yang F; Miller D; Johnson SL; Stewart MW; Leiter LA;
Diabetes Care; 2014 Aug; 37(8):2317-25. PubMed ID: 24898300
[TBL] [Abstract][Full Text] [Related]
7. A clinical utility index for selecting an optimal insulin dosing algorithm for LY2605541 in patients with type 2 diabetes pretreated with basal insulin.
Manner DH; Luo J; Qu Y; Berry S; Gaydos BL; Jacober SJ
Diabetes Technol Ther; 2014 Aug; 16(8):499-505. PubMed ID: 24825416
[TBL] [Abstract][Full Text] [Related]
8. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes.
Buse JB; Wolffenbuttel BH; Herman WH; Shemonsky NK; Jiang HH; Fahrbach JL; Scism-Bacon JL; Martin SA
Diabetes Care; 2009 Jun; 32(6):1007-13. PubMed ID: 19336625
[TBL] [Abstract][Full Text] [Related]
9. Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus.
Sinha VP; Howey DC; Choi SL; Mace KF; Heise T
Diabetes Obes Metab; 2014 Apr; 16(4):344-50. PubMed ID: 24118909
[TBL] [Abstract][Full Text] [Related]
10. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.
Malone JK; Kerr LF; Campaigne BN; Sachson RA; Holcombe JH;
Clin Ther; 2004 Dec; 26(12):2034-44. PubMed ID: 15823767
[TBL] [Abstract][Full Text] [Related]
11. Durability of glycemic control with insulin lispro mix 75/25 versus insulin glargine for older patients with type 2 diabetes.
Jovanovič L; Peters AL; Jiang HH; Hardin DS
Aging Clin Exp Res; 2014 Apr; 26(2):115-21. PubMed ID: 24092662
[TBL] [Abstract][Full Text] [Related]
12. Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8.
Harris C; Forst T; Heise T; Plum-Mörschel L; Watkins E; Zhang Q; Fan L; Garhyan P; Porksen N
Diabetes Technol Ther; 2017 Aug; 19(8):463-470. PubMed ID: 28817342
[TBL] [Abstract][Full Text] [Related]
13. Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial.
Tinahones FJ; Gross JL; Onaca A; Cleall S; Rodríguez A
Diabetes Obes Metab; 2014 Oct; 16(10):963-70. PubMed ID: 24725616
[TBL] [Abstract][Full Text] [Related]
14. A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1.
Garg S; Dreyer M; Jinnouchi H; Mou J; Qu Y; Hartman ML; Rosilio M; Jacober SJ; Bastyr EJ;
Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():25-33. PubMed ID: 27393697
[TBL] [Abstract][Full Text] [Related]
15. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
16. Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial.
Koivisto V; Cleall S; Pontiroli AE; Giugliano D
Diabetes Obes Metab; 2011 Dec; 13(12):1149-57. PubMed ID: 21819517
[TBL] [Abstract][Full Text] [Related]
17. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
[TBL] [Abstract][Full Text] [Related]
18. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
Yki-Järvinen H; Dressler A; Ziemen M;
Diabetes Care; 2000 Aug; 23(8):1130-6. PubMed ID: 10937510
[TBL] [Abstract][Full Text] [Related]
19. Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial.
Arakaki RF; Blevins TC; Wise JK; Liljenquist DR; Jiang HH; Jacobson JG; Martin SA; Jackson JA
Diabetes Obes Metab; 2014 Jun; 16(6):510-8. PubMed ID: 24298995
[TBL] [Abstract][Full Text] [Related]
20. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes.
Malone JK; Bai S; Campaigne BN; Reviriego J; Augendre-Ferrante B
Diabet Med; 2005 Apr; 22(4):374-81. PubMed ID: 15787659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
